Migraines and Menopause – A Narrative Review

(Bernstein & O'Neal - Link here)

This paper looks at what happens to head-pain patterns as women move through perimenopause into menopause, why those patterns often change, and what the research says about hormone therapy for women who experience migraines.

Key findings

• Perimenopause often brings more frequent head-pain episodes.
  Estrogen becomes unpredictable during this transition — rising, falling, and spiking — and migraines tend to flare when estrogen swings sharply.
• After menopause, patterns may shift — but not for everyone.
  Once hormones settle into a low, stable pattern, many women notice fewer migraines. Others continue to experience them, sometimes with different patterns or triggers.
• Migraine with aura is associated with a modestly elevated vascular risk.
  The authors note this is worth factoring into the overall picture in midlife, when age, blood pressure, and lifestyle also contribute to cardiovascular considerations.
• Women with migraines are not automatically excluded from hormone therapy options.
  The authors note that menopausal hormone therapy uses much lower doses of estrogen than birth control pills.
  • Lower, steadier estrogen — especially through the skin — may actually reduce the hormonal instability that drives some migraine patterns.
  • Research emphasizes that individual circumstances — including overall cardiovascular picture — shape which hormonal approaches may be appropriate.

The takeaway: perimenopause is a volatile time for hormones — and for head pain. Stable, low-dose hormone approaches are an area of active research for women whose migraines appear tied to hormonal swings.

Migraines in Women: A Focus on Reproductive Events and Hormonal Milestones

(Kim & Park - Link here).

This article explores how migraines shift across a woman's life: puberty, menstrual cycles, pregnancy, postpartum, birth control use, perimenopause, and menopause — and why hormones sit at the center of these changes.

Key findings

• Female migraines are strongly hormone-driven.
  Estrogen is involved in several brain chemistry systems linked to migraine — serotonin, dopamine, glutamate, and GABA — which helps explain why women's head-pain patterns often follow hormonal rhythms.
• Estrogen withdrawal is a major trigger.
  Drops in estrogen — before a period, postpartum, and during perimenopause — are associated with activation of pain pathways in the brain.
• Women appear to have a stronger response to CGRP.
  CGRP (a molecule closely studied in migraine research) appears to have more pronounced effects in females, which research suggests may help explain why women experience migraines more often than men.
• Perimenopause brings unpredictable hormonal changes.
  Because hormone levels rise and fall irregularly during this transition, many women notice more frequent migraine episodes.
• After menopause, patterns often stabilize.
  Post-menopause, estrogen stays low but steady — and research suggests this stability can reduce hormonally sensitive migraine patterns for many women.

Bottom line: hormones shape head-pain patterns across a woman's entire reproductive life. Estrogen fluctuations — not just low levels — appear to be a major driver, especially during perimenopause.

Menopause Hormone Therapy, Migraines, and Thromboembolism

(Khandelwal, Meeta, Tanvir - Link here).

This article focuses on how menopausal hormone therapy interacts with migraine history and blood-clot risk — and what the research suggests about navigating both.

Key findings

• Migraine history does not automatically rule out hormone therapy options.
  Earlier assumptions placed migraine broadly in the "avoid hormones" category. Newer research shows that menopausal hormone therapy uses much gentler doses than contraceptives — a meaningful distinction.
• Migraine with aura is associated with modestly elevated vascular risk — but the full picture matters.
  Factors like smoking, hypertension, or metabolic health influence overall risk far more than migraine history alone.
• Transdermal estrogen keeps hormone levels steadier.
  This delivery route avoids first-pass liver processing, and research suggests it may be gentler on clotting factors than oral forms — which is particularly relevant for women with cardiovascular considerations.
• Stable estrogen appears better than fluctuating estrogen for migraine-prone women.
  The review notes that continuous regimens avoid the sharp hormonal swings that cyclic approaches can produce — swings that research associates with increased head-pain episodes.
• Progestogen choice matters too.
  More physiologically similar progesterone options (such as micronized progesterone) may be better tolerated by women who are sensitive to hormonal fluctuations.

In short: for women whose migraines appear tied to hormonal instability, the research suggests that hormone therapy options — particularly those that deliver steady, low levels of estrogen — are worth discussing with a knowledgeable healthcare provider who can assess the full individual picture.

Why These Three Articles?

Across all three reviews, several shared themes emerge:

1. Head pain in midlife is largely about hormonal instability.

All three papers emphasize that perimenopause — a time of irregular, unpredictable estrogen fluctuations — is commonly associated with more frequent migraines. Stability, not "higher estrogen," is what the research points to.

2. Migraine history doesn't automatically close the door on hormone therapy conversations.

Both Bernstein & O'Neal and Khandelwal et al. note that menopausal hormone therapy is very different from birth control pills. Lower doses and transdermal delivery routes change the risk calculation meaningfully.

3. Migraine with aura warrants a careful look — not a blanket exclusion.

Aura is associated with modestly elevated vascular risk, but total risk depends on the whole picture: smoking status, blood pressure, age, metabolic factors, and the specific hormonal approach.

4. Hormones influence head-pain patterns through multiple brain pathways.

Kim & Park detail the "why": estrogen is involved in serotonin, dopamine, glutamate, GABA, and CGRP systems — all closely tied to migraine pathways. The other two papers reference these mechanisms when explaining why hormonal stability may help some women.

5. After menopause, head-pain patterns often settle down.

Once hormones become steady — even at lower levels — many women notice fewer or less volatile migraine patterns. All three papers mention this finding.